The Waltham, MA-based biotech said its Phase III trial for niraparib hit its primary endpoint of progression-free survival (PFS) against placebo across several sets of patients--including those who were positive for germline BRCA mutation, and another set that do not carry this mutation--as well as those who have homologous recombination deficient (HRD) tumors as determined by a diagnostic kit.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.